Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Novo Nordisk's net profit in the third quarter rose 21% to 27.3 billion kroner, ahead of the 26.79 billion kroner forecast by analysts in a FactSet poll. Sales rose 21% to 71.31 billion kroner, ...

Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and ...

Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.